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Original research article
Estimating the number of UK stroke
patients eligible for endovascular
thrombectomy
Peter McMeekin1,2, Philip White3, Martin A James4,
Christopher I Price3, Darren Flynn1 and Gary A Ford5
Abstract
Introduction: Endovascular thrombectomy is a highly effective treatment for acute ischemic stroke due to large arterial
occlusion. Routine provision will require major changes in service configuration and workforce. An important first step is
to quantify the population of stroke patients that could benefit. We estimated the annual UK population suitable for
endovascular thrombectomy using standard or advanced imaging for patient selection.
Patients and methods: Evidence from randomised control trials and national registries was combined to estimate UK
stroke incidence and define a decision-tree describing the endovascular thrombectomy eligible population.
Results: Between 9620 and 10,920 UK stroke patients (approximately 10% of stroke admissions) would be eligible for
endovascular thrombectomy annually. The majority (9140–9620) would present within 4 h of onset and be suitable for
intravenous thrombolysis. Advanced imaging would exclude 500 patients presenting within 4 h, but identify an additional
1310 patients as eligible who present later.
Discussion: Information from randomised control trials and large registry data provided the evidence criterion for 9 of
the 12 decision points. The best available evidence was used for two decision points with sensitivity analyses to deter-
mine how key branches of the tree affected estimates. Using the mid-point estimate for eligibility (9.6% of admissions)
and assuming national endovascular thrombectomy coverage, 4280 patients would have reduced disability.
Conclusion: A model combining published trials and register data suggests approximately 10% of all stroke admissions
in the UK are eligible for endovascular thrombectomy. The use of advanced imaging based on current published evidence
did not have a major impact on overall numbers but could alter eligibility status for 16% of cases.
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Introduction
Endovascular thrombectomy (EVT) is an eﬀective
treatment for acute ischemic stroke with or without
intravenous alteplase.1–8 The HERMES9 individual
patient meta-analysis found that for every ﬁve patients
treated with EVT, two would have reduced disability
by at least one level on the modiﬁed Rankin Scale
(mRS). However, providing EVT presents major chal-
lenges in many health care systems. The procedure is
typically carried out by neuro-interventionists with
anaesthetic support, and requires an infrastructure
capable of rapidly performing computed tomography
angiography (CTA), with or without advanced ima-
ging (AI) by perfusion-computed tomography (CTP),
magnetic resonance imaging (MRI) techniques or
CTA collateral scoring (CTA-CS). In clinical trials,
CTA alone was generally used to select patients
within 6 h of onset, whereas AI techniques were used
beyond and sometimes before a 6-h window. The
1Institute of Health and Society, Newcastle University, Newcastle Upon
Tyne, UK
2Faculty of Health and Life Sciences, Northumbria University, UK
3Institute of Neuroscience (Stroke Research Group), Newcastle
University, Newcastle Upon Tyne, UK
4NIHR Collaboration for Leadership in Applied Health Research and
Care for the South West Peninsula (PenCLAHRC), Exeter, UK
5Oxford University Hospitals NHS Trust and Oxford University, UK
Corresponding author:
Peter McMeekin, Faculty of Health and Life Sciences, Northumbria
University, Newcastle upon Tyne NE7 7AX, UK.
Email: peter.mcmeekin@northumbria.ac.uk
European Stroke Journal
2017, Vol. 2(4) 319–326
! European Stroke Organisation
2017
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/2396987317733343
journals.sagepub.com/home/eso
additional infrastructure demands for EVT create the
need for a more centralised model of hyperacute
stroke care, and robust activity estimates are required
for accurate planning to inform service
reconﬁguration.
In seeking to estimate the anticipated annual
demand for this treatment in the UK, we developed a
decision tree to estimate the proportion of all stroke
patients eligible for EVT, regardless of geographic or
service constraints such as non-existent care pathways
or a lack of imaging and EVT facilities.
Patients and methods
Using national registry data from the prospective
Sentinel Stroke National Audit Programme (SSNAP)
for England, Wales and Northern Ireland,10 and
adjusted for Scotland using data from the Scottish
Stroke Care Audit (SSCA),11 we estimated the
number of patients hospitalised annually with acute
stroke. A decision tree was constructed based upon
key inclusion and exclusion criteria from published
trials: stroke type, severity, presence of anterior or
posterior large artery occlusion (LAO), onset time,
pre-stroke disability, the extent of ischemia on CT (or
MRI), pre-EVT recanalisation and optional AI. These
criteria were applied consistently irrespective of eligibil-
ity for intravenous thrombolysis (IVT). The distribu-
tions for stroke severity and onset time were extracted
from two large UK stroke services. The ﬁnal decision
tree has 12 steps and includes pathways using AI within
and beyond 6 h after stroke onset. We did not include
basilar artery occlusions presenting after 12 h, as
quantifying these at a national level is imprecise.
We undertook sensitivity analyses of key decision
points to determine the eﬀect upon estimates (propor-
tion of LAO cases, clinical severity, onset time to pres-
entation and core volume).
Results
Estimating annual stroke admissions in the UK
The decision tree is presented in Figure 1. It begins with
an estimate of annual UK stroke admissions derived
from SSNAP and SSCA. SNNAP coverage is compre-
hensive, with over 80,000 admissions recorded in 2015
from 100% of acutely-admitting hospitals. Case ascer-
tainment in SNNAP is over 98% in England when ver-
iﬁed against Hospital Episode Statistics, with the
majority of cases omitted being sub-acute or otherwise
ineligible for acute intervention. Scaling up this ﬁgure
by the populations of Wales and Northern Ireland
added 4480 and 2240 admissions, respectively. With
8700 admissions from the SSCA, total stroke
admissions (excluding subarachnoid haemorrhage) for
the UK are 95,500.
Eligibility by stroke type, location and severity
SSNAP10 and SSCA11 data report that 13% and 12%
stroke admissions respectively are due to intracerebral
haematoma. The proportion of ischemic strokes caused
by LAO was observed at approximately 41% by the
Screening Technology and Outcome Project in Stroke
Study (STOP-Stroke), a prospective imaging-based
study of stroke outcomes,12 and in the trials contribut-
ing to the HERMES meta-analysis.9 This is supported
by a recent UK study of 263 patients reporting a 39%
LAO rate.13
‘Minor strokes’ (a National Institutes of Health
Stroke Scale [NIHSS] score below 6) are not conclusively
proven to beneﬁt from EVT and were therefore not
included in the eligible population.9 Whilst the
HERMES meta-analysis applied a cut-oﬀ of
NIHSS 10 (showing a strong trend towards beneﬁt
but without statistical signiﬁcance), there was no evi-
dence of heterogeneity in treatment eﬀect by NIHSS.
However, individual trials have shown beneﬁt from
EVT with an NIHSS of 6 or more: ESCAPE
(Endovascular Treatment for Small Core and Anterior
Circulation Proximal Occlusion with Emphasis on
Minimizing CT to Recanalization Times)3 and SWIFT
PRIME (Solitaire FR With the Intention for
Thrombectomy as Primary Endovascular Treatment
for Acute Ischemic Stroke)4; and NIHSS of 8 or more:
REVASCAT (Randomized Trial of Revascularization
With Solitaire FR Device Versus Best Medical
Therapy in the Treatment of Acute Stroke Due to
Anterior Circulation Large Vessel Occlusion Presenting
Within 8Hours of Symptom Onset).5 Only MR CLEAN
(Multicenter Randomized Clinical Trial of Endovascular
Treatment for Acute Ischemic Stroke in the
Netherlands)1 speciﬁcally enrolled patients with NIHSS
below 6 and failed to show statistically signiﬁcant beneﬁt
from EVT in the subgroup with NIHSS 2–15. Taking
account of these data, we applied an NIHSS cut-oﬀ of 6
aligning with the three trials that included the largest
numbers of patients in the NIHSS range 6–10.
The STOP-Stroke study12 reported that 20% of
LAO strokes had an NIHSS of less than 6 (decision-
point C). This was reinforced by El Tawil et al.13 These
proportions give an estimate of 26,590 moderate/severe
stroke patients (NIHSS 6 or more) with LAO in the
UK annually.
Time of onset and eligibility
Eligible stroke patients were deﬁned as those with
a known stroke onset time of less than 12 h before
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Figure 1. Eligible population ((a) Total UK population including those deemed to be geographically inaccessible. (b) Confirmed
infarcts, excluding 2% of patients whose status is unconfirmed. (c) Includes basilar artery occlusions eligible for treatment if
presenting within 12 h. Others are assumed eligible unless they meet any subsequent exclusion. (d) ‘Early presenters’ – those pre-
senting within 4 h.) Note: Patients within the large lower grey shaded box are all dealt with by AI (9400þ 10,130) those who are early
presenters (10,130 on the left-hand side) can bypass that step.
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presentation or were Stroke with Unknown Time
of Onset (SUTO) with a Last Seen Well (LSW)
time within 12 h. No recent published thrombec-
tomy trial has included patients beyond this time
period.
A distribution of presentation times was derived
from SNNAP10 but this was not reported by stroke
severity. Stratiﬁcation by severity was performed
using service level SSNAP data for the calendar
year 2015 from a single large UK acute stroke unit
(Northumbria Healthcare NHS Foundation Trust:
900 admissions annually) and for three years from
a second unit (Royal Devon and Exeter NHS
Foundation Trust: 700 admissions annually), which
showed that 78% of stroke patients with NIHSS of
6 or more presented within 12 h of onset. The
SSNAP ﬁgure for all stroke cases presenting within
12 h was lower at 55% which is consistent with
Northumbria and Devon and Exeter data if later
presentation of milder cases is accounted for. For
the remaining 22% of patients with NIHSS of 6 or
more, SNNAP data enabled estimation of the relative
proportions presenting with (a) SUTO but LSW
within 12 hours (68.5%) and (b) a known onset
time greater than 12 h (31.5%; Figure 1, decision-
point E).
According to SSNAP10 data, 81% patients present
with a known time of onset, of whom 60% are within
4 h and 21.1% between 4 and 12 h (with 18.9% after
12 h). Therefore, the split between those presenting
within 4 h and those between 4 and 12 h is 74% and
26%, respectively (Figure 1, decision-point F). After
exclusions for onset time, stroke type, severity and
location, the decision tree contains two cohorts of
patients potentially eligible for EVT: ‘early presenters’
– i.e. those presenting within 4 h (mostly eligible for
IVT within 4.5 h) and ‘late presenters’ – those ineli-
gible for IVT because either their stroke onset was 4–
12 h ago, or they were SUTO but LSW within 12 h. At
this point in the decision tree, approximately 24,750
(25%) of stroke admissions are potentially eligible for
EVT (9400þ 15,350). It was assumed that only ‘early
presenters’ would be able to receive EVT treatment
within 6 h of onset.9 Trial data indicate that from
arrival at thrombectomy centre to arterial puncture
it will take >60min on average to groin puncture
and at least another 45min for recanalisation to
be achieved.14 In addition, the majority of UK
patients will require secondary transfer for EVT
after initial local assessment. For late presenting
patients (arrive beyond 4 h post onset), it was assumed
that IVT would not be used. From this point in our
decision tree, the two groups (Figure 1, decision-
points G and H) are diﬀerentially inﬂuenced by appli-
cation of AI.
Clinical and radiological exclusions amongst the IVT
eligible population
The largest group eligible for EVT were those early
presenters i.e. 13,770 (14% of all stroke admissions).
Further EVT exclusions associated with little prospect
of successful reperfusion were a CT ASPECTS (Alberta
Stroke Programme Early CT Score)15 of less than 6 or
visible infarction of more than one-third of the middle
cerebral artery (MCA) territory, and a pre-stroke mRS
of 3 or more. As only 1.6% of the HERMES patients
had an mRS of 3 or more, this group are excluded as
EVT beneﬁt is unproven. The STOP-Stroke study12
identiﬁed 8.7% of LAO stroke patients with a pre-
stroke mRS of 3 or more, which is not dissimilar to
reports from the study logs of trials included in
HERMES.9
The HERMES meta-analysis reported that an
ASPECTS of 0–5 did not demonstrate a statistically
signiﬁcant treatment beneﬁt (odds ratio [OR] 1.24,
0.62–2.49)9 possibly because numbers in this category
were small (9%). In contrast, clear beneﬁt for EVT was
demonstrated with a presentation ASPECTS score of
6–8 and 9–10. To estimate the diﬀerential impact on
outcome of early radiological changes, we applied a
post hoc analysis of the Interventional Management
of Stroke (IMS)-3 trial CTA positive subgroup data,14
which reported LAO on CTA in 40/282 participants
(14%) with ASPECTS 0–4 and 88/282 (31%) with
ASPECTS 5–7. We allocated these proportions equally
to each ASPECTS score, yielding an estimated propor-
tion of almost 25% for ASPECTS 0–5 in proven LAO.
A pre-stroke mRS of 3 or more, and/or ASPECTS of
0–5 would, therefore, exclude approximately 34%. It
was assumed that no overlap exists between these two
criteria as we were unable to identify any reports of an
association between pre-stroke disability and the sever-
ity of early ischemic changes assessed by ASPECTS or
any other method. Therefore, amongst the early pre-
senting IVT eligible population, we estimated that
10% of total stroke admissions were eligible for EVT,
before any AI exclusions. This equates to 10,130
patients per year (Figure 1, decision-point G).
Various modes of AI (CT-CTP, CTA-CS combined
with ASPECTS, or MRI) have been proposed for the
exclusion of patients with a large core infarct. Data
from the EXTEND-IA (Extending the Time for
Thrombolysis in Emergency Neurological Deﬁcits–
Intra-Arterial)2 trial and the Sistema Online
d’Informacio´ de l’Ictus Agut (SONIIA)16 Registry
suggest that AI excludes a further 5% of those early
presenters with moderate/severe LAO stroke and pre-
stroke mRS below 3 because they have a large volume
core and small penumbra. If optional AIs were used in
the early presenting group, the decision tree shows that
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a further 500 patients would be excluded, leaving an
EVT eligible population of 9620 patients, before any
recanalisation (Figure 1, decision-point I).
Clinical and radiological exclusions amongst the
late presenting/SUTO population ineligible for IVT
In the group presenting with SUTO but LSW within
12 h, or with a known onset time between 4 and 12 h,
information about EVT eligibility is less robust and
reliant upon variable AI protocols. Within our popula-
tion of moderate-to-severe ischemic strokes with LAO,
we estimate 5390 would have a known time of onset
between 4 h to 12 h. We also estimated from SSNAP
that a population of 4010 would be LSW within 12 h,
giving a population of 9400 in whom AI might identify
salvageable brain tissue, the majority of whom would
also have a pre-stroke mRS below 3 (Figure 1, decision-
point H).
To identify the proportion of this group excluded by
imaging, data from SWIFT17 and IMS-318 trials were
used. At baseline, 25% had an ASPECTS below 6.
Furthermore, by comparing ASPECTS at baseline to
follow-up (mostly at 24 h), 48% deteriorated from good
to poor ASPECTS.16 It is assumed that this deterior-
ation represented core infarct extension occurring
within 12 h. Therefore, in total 73% of ‘late-presenting’
patients are excluded by an ASPECTS below 6 on ini-
tial CT. Clinical mRS exclusions (as in the early-
presenting group) would exclude another 8%12 or 203
(of the remaining 2538 late-presenting patients with an
ASPECTS score indicative of limited acute ischaemic
damage), leaving a total of 2340 of 9400 eligible for AI
(Figure 1, decision-point H). That is 75% of 9400 are
excluded.
Data from the CTP group in MR CLEAN19 indi-
cate that 43% had a large core of greater than 70mL
(using the deﬁnition applied in EXTEND2 and
SWIFT-PRIME4 trials). Applying this proportion
means that 1330 of the group remained deﬁnitely eli-
gible for EVT (i.e. they had a smaller core and a
larger volume of salvageable penumbral tissue;
Figure 1, decision-point K).
Recanalisation prior to EVT
Our estimates identify 9620 or 10,920 patients eligible
for EVT, depending upon whether AI is used to iden-
tify salvageable brain tissue in those early presenters.
A small proportion of these patients will recanalise
spontaneously or in response to IVT before EVT is
performed. The HERMES trials indicate that this
occurred in 5% of those receiving IVT. Spontaneous
recanalisation among patients not receiving IVT is
estimated at 2% based on expert consensus (PW,
GF, MJ), and the ﬁnding from the PROACT-II trial
(Prolyse in Acute Cerebral Thromboembolism II),20 in
which 2% of patients in the placebo arm had TIMI 3
(Thrombolysis in Myocardial Infarction rating scale
[in which three represents complete recanalisation]);
in this context, any recanalisation that is less than
complete would not exclude EVT. Thus recanalisation
prior to EVT excludes 510 patients (480 if the AI
pathway followed) from the early presenting popula-
tion presenting (Figure 1, decision-points J).
Spontaneous recanaliation would exclude 30 patients
from the late presenting/SUTO group (Figure 1, deci-
sion-point L).
Sensitivity analyses
Results of sensitivity analyses are shown in Table 1. For
LAO, we identiﬁed retrospective study extremes
between 13%21 and 88%,22 which were regarded as
unreliable for modelling. More robust data from a pro-
spective cohort reported a lower LAO estimate of
33%,23 and the EXTEND-IA2 screening log-identiﬁed
LAO in 53% of IVT-eligible patients, so these data
were used as the basis for a 30–50% range of LAO
incidence. In the absence of other credible data sources,
a pragmatic 10% range was also used for exclusion by
onset time, ASPECTS, mRS and the proportion
excluded due to a large core. The LAO proportion
and the numbers of patients presenting with a known
onset time within 12 h, had the greatest impact on the
estimates of eligibility.
Table 1. Univariate sensitivity analyses.
Decision point Value (%) Eligible population
Proportion of LAO strokes
High value 50 12,030–13,670
Low value 30 7220–8200
Proportion of moderate/severe strokes
presenting early
High value 88 10,860–12,100
Low value 68 8390–9860
Proportion of late-presenting patients excluded
by ASPECTS and mRS of 3 or more
High value 65 9620–11,460
Low value 85 9620–10,410
Proportion of late-presenting patients
with large core
High value 33 9620–11,170
Low value 53 9620–10,710
ASPECTS: Alberta Stroke Programme Early CT Score; LAO: large artery
occlusion; mRS: modified Rankin Scale.
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Discussion
Based on the available evidence from intervention trials
and prospective registries in EVT, we estimate 9140–
10,920 patients in the UK with acute ischemic stroke
are eligible for EVT annually i.e. approximately 10%
of strokes admitted to hospital. This is consistent with
other reports. Chia et al.22 estimated a range of 7–13%
for EVT eligibility presenting to two of three Australian
hyper-acute stroke sites serving a population of approxi-
mately 150,000. The lower bound of our estimate is
deﬁned by restricting EVT only to those early presenters
(9620/year). The upper bound is deﬁned by the inclusion
of all early-presenting patients without the use of AI
(9620/year) to which are added those late-presenting
patients with a favourable imaging proﬁle (1310/year).
AI would exclude around 5% (500/10,130) of early-pre-
senting and otherwise eligible patients from EVT but
would include around 56% (1310/2350) of late-present-
ing (IVT-ineligible) patients as eligible for EVT. Thus,
although the overall requirement (eligibility) for EVT is
relatively unchanged by AI, its use would aﬀect EVT
treatment decisions in approximately 15% (1810/
12,470) of otherwise eligible patients.
Where possible our decision points are based upon
the large prospective SSNAP registry, which covers the
UK excluding Scotland. Case ascertainment by SSNAP
in England (population 55 million) exceeds 98%.
SSNAP or randamised controlled trials (RCTs) data
provide the main evidence criterion for 9 of the 12 deci-
sion points. The main uncertainties are in the smaller
group of late-presenting patients with LAO and NIHSS
greater than 6, for whom limited high-quality data are
available around eligibility for EVT (decision-point H)
since this population was the least represented in the
trials. However, this group is small and sensitivity ana-
lyses show that changing assumptions have little impact
upon model outcomes.
The proportion of patients considered appropriate
for EVT is dependent upon the frequency of LAO,
but previous reports vary. Amongst the recent thromb-
ectomy trials which reported screening and eligibility
data, the rate of LAO was 53% in EXTEND-IA2 and
48% in SWIFT PRIME.4 Rai et al.21 estimated the
incidence of LAO from a retrospective sample of
nearly 3000 patients referred to a tertiary-level aca-
demic hospital in West Virginia, over 90% of whom
had CTA, with LAO demonstrated in only 12%.
However, complete case ascertainment is uncertain as
many patients were secondary transfers, and over 70%
of LAO were M1 occlusions. Smith et al.12 identiﬁed,
after expert review, an LAO rate of 46% in patients
with conﬁrmed stroke referred to two large academic
US centres, using a broader deﬁnition which included
the anterior and posterior cerebral arteries, and secon-
d-order branches (so M2). A recent prospective study in
the UK identiﬁed an LAO rate of 39%.13 Our rate of
LAO at 40% may be a small overestimate, but we con-
sider this to be based on the most reliable information
available.
The selection of patients by AI based upon current
best evidence had relatively little eﬀect on the overall
numbers eligible for treatment but altered the eligibility
decision in 15% of cases. The impression that a rela-
tively small proportion of early-presenting patients with
LAO on CTA would be subsequently ruled out by AI
(5% in our model) is corroborated by EXTEND-IA2
trial. The results from the DAWN trial (NCT02142283)
will be valuable for clarifying the proportion of patients
with an unknown symptom onset time who should be
oﬀered EVT according to AI.
With no formally commissioned services, the UK is
starting from a low baseline; in 2017, NHS England
anticipates funding treatment of 1000 patients in the
ﬁrst year of formal commissioning. The midpoint of
our estimate for a UK population suitable for EVT
(10.8% of all stroke admissions) combined with the
absolute beneﬁts estimated in a recent individual
patient data meta-analysis24 suggest that EVT with
national coverage could achieve an additional 2420
patients with independent functional outcomes, or as
many as 4280 patients (4% all stroke admissions)
with a reduced level of disability compared to IVT
alone. Implicit in this estimates is the assumption that
outcomes for posterior circulation EVT (which are
included in our estimates of eligible population) are
the same as those for anterior circulation EVT. There
is an absence of evidence about posterior circulation
EVT, but in light of outcomes for basilar artery occlu-
sions treated with IVT, we judge this assumption rea-
sonable at this time. Based on a range of estimates, the
mean monthly cost to the UK National Health Service
and social care providers of caring for people who lose
their independence because of stroke (an mRS of 3, 4 or
5) was estimated at £790 (US$1,300/E980 at 2014
exchange rates) at 2013–2014 prices.25 Assuming 2420
people would maintain independence because of EVT,
the savings (before costs for EVT are included) over 12
months post-stroke are greater than £22 million (US
$36 million/E27 million at 2014 exchange rates).
A cost-eﬀectiveness analysis from the US26 reported
that EVT is a highly cost-eﬀective intervention in the
prevention of stroke-related disability with an
incremental cost-eﬀectiveness ratio of $3,000 per qual-
ity-adjusted life year (QALY). A more recent study
projected that EVT dominated thrombolysis alone
when future savings from reduced social care need
were included, and despite the higher costs of providing
EVT, there was a saving of £30,000 over a patient’s
lifetime to health and social care providers and before
the consequences of lost productivity in the working
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age stroke population were accounted for.27 This
equates each year in the UK, to a net realisable
saving of £73 million each year over patient’s lifetimes.
Conclusion
Between 9620 and 10,920 stroke patients per year in the
UK could be eligible for EVT based on current level-1
evidence, which approximates to 10% of stroke admis-
sions. Given the magnitude of the potential clinical and
wider economic beneﬁts from EVT, it should now be a
key priority to address the substantial infrastructure
and workforce obstacles impeding rapid and wide-
spread implementation.
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